Ali Behbahani's Net Worth

$62.6 Thousand

Estimate Recalculated Sep 17, 2024 07:57PM EST

Who is Ali Behbahani?

Ali Behbahani does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Nkarta, Inc., NeueHealth, Inc., Monte Rosa Therapeutics, Inc., Oyster Point Pharma, Inc., NEVRO CORP, Mirum Pharmaceuticals, Inc., Adaptimmune Therapeutics PLC, CRISPR Therapeutics AG, GENOCEA BIOSCIENCES, INC., Metacrine, Inc., CVRx, Inc., Arcellx, Inc., Savara Inc, Trevi Therapeutics, Inc., MINERVA SURGICAL INC, Akouos, Inc., Black Diamond Therapeutics, Inc., Arsanis, Inc., Regulus Therapeutics Inc., Marker Therapeutics, Inc., and Korro Bio, Inc..

SEC CIK

Ali Behbahani's CIK is 0001613867

Past Insider Trading and Trends

2021 was Ali Behbahani's most active year for acquiring shares with 23 total transactions. Ali Behbahani's most active month to acquire stocks was the month of May. 2021 was Ali Behbahani's most active year for disposing of shares, totalling 10 transactions. Ali Behbahani's most active month to dispose stocks was the month of September. 2022 saw Ali Behbahani paying a total of $168,748.48 for 903,630 shares, this is the most they've acquired in one year. In 2023 Ali Behbahani cashed out on 36,525 shares for a total of $0.00, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Nkarta, Inc. (NKTX) Snapshot price: $5.2

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Jun 13
Form 4
—
0
—
—
0
Jun 7
Form 4
—
0
—
—
0
Jun 8
Form 4
—
0
—
—
0
Jun 13
Form 4
—
0
—
—
0
Jul 9
Form 3
—
0
—
—
0
No matching records found

NeueHealth, Inc. (BHG) No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Apr 8
Form 4
—
0
—
—
0
Dec 19
Form 4
—
0
—
—
0
Oct 31
Form 4
—
0
—
—
0
Sep 15
Form 4
—
0
—
—
0
Aug 11
Form 4
—
0
—
—
0
Oct 17
Form 4
—
0
—
—
0
Jan 3
Form 4
∞
71.91M
$18.00
—
71.91M
Jun 28
Form 3
—
0
—
—
0
No matching records found

Monte Rosa Therapeutics, Inc. (GLUE) Snapshot price: $5.69

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Jun 12
Form 4
—
0
—
—
0
Jun 14
Form 4
—
0
—
—
0
Jun 15
Form 4
∞
7.69M
$19.00
—
7.69M
Jun 28
Form 4
—
0
—
—
0
Jun 23
Form 3
—
0
—
—
0
No matching records found

Oyster Point Pharma, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-13.64K
—
—
0
Jan 3
Form 4
+35.50%
3.57K
—
—
13.64K
Jun 6
Form 4
+52.52%
3.47K
—
—
10.07K
Jun 7
Form 4
∞
6.6K
—
—
6.6K
Jun 8
Form 3
—
0
—
—
0
No matching records found

NEVRO CORP (NVRO) Snapshot price: $5.09

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+235.83%
3.79K
—
—
5.39K
May 21
Form 4
+2.56%
40
—
—
1.6K
Sep 14
Form 4
+3,229.79%
1.52K
—
—
1.56K
May 25
Form 4
+88.00%
22
—
—
47
Nov 11
Form 4
—
0
—
—
0
May 18
Form 4
∞
25
—
—
25
Dec 2
Form 4
—
0
—
—
0
May 28
Form 4
—
0
—
—
0
Nov 5
Form 3
—
0
—
—
0
No matching records found